Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients
Pexels / Pixabay

Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients

According to a story from Juvenile Arthritis News, a recent study from China has found that early treatment with infliximab (marketed as Remicade) can reduce inflammation and indicators of active…

Continue Reading Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients

Preclinical Findings for Phenylketonuria and Metachromatic Leukodystrophy Gene Therapies Look Promising

According to a story from BioSpace, the genetic medicines company Homology Medicines, Inc., has recently released preclinical data supporting the development of two experimental gene therapies. One, called HMI-202, is…

Continue Reading Preclinical Findings for Phenylketonuria and Metachromatic Leukodystrophy Gene Therapies Look Promising

The First Clinical Evidence that the Drug Mavoglurant Improves Responsiveness in Fragile X Syndrome (FXS)

Results of a study reported in PLOS ONE that was conducted by a team of scientists indicate that the experimental drug mavoglurant improves responsiveness and eye gaze for patients with…

Continue Reading The First Clinical Evidence that the Drug Mavoglurant Improves Responsiveness in Fragile X Syndrome (FXS)

First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease

Actus Therapeutics, a privately held portfolio company of AskBio, has recently announced through PRWeb, the initiation of patient dosing in a clinical trial testing its investigational gene therapy ACTUS-101. About Pompe…

Continue Reading First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
Healx Ltd. Raises $56 Million to Use Artificial Intelligence to Sped Up Rare Disease Drug Trials
Seanbatty / Pixabay

Healx Ltd. Raises $56 Million to Use Artificial Intelligence to Sped Up Rare Disease Drug Trials

As originally reported in South Africa Latest News, Healx Ltd. has raised $56 million dollars to fund their development of treatment options for rare diseases using artificial intelligence. The British…

Continue Reading Healx Ltd. Raises $56 Million to Use Artificial Intelligence to Sped Up Rare Disease Drug Trials
Close Menu